Omeros defends its drug, but still won’t answer basic questions
Omeros sought to defend its experimental drug OMS721 with a press release responding to my questions about the drug. But it didn't clear much up.
STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.
